Study confirms safety of Bionor’s Vacc-4x, as a potential cure for HIV
Norway’s Bionor Pharma (OSE: BIONOR) has released promising results from an interim analysis of Part B of the REDUC study. Bionor’s shares rose 7.3% to 3.10 Norwegian kroner in midmorning trading.
In the study, Bionor’s safe and tolerated vaccine candidate Vacc-4x and the HDAC inhibitor romidepsin (Istodax, Celgene) are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment.
The REDUC study is a Phase I/II trial, and a first step in validating Bionor’s strategy for Vacc-4x which the company sees as a component in a potential functional cure for HIV. Bionor has previously successfully completed a study of Vacc-4x, with Celgene’s immunomodulator, Revlimid (lenalidomide; The Pharma Letter June 14, 2013).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze